| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2023 | 285.26% | HC Wainwright & Co. | $55 → $46 | Maintains | Buy |
| 08/10/2023 | 318.76% | Wells Fargo | $51 → $50 | Maintains | Overweight |
| 08/10/2023 | 218.26% | Wedbush | → $38 | Reiterates | Outperform → Outperform |
| 08/10/2023 | 360.64% | HC Wainwright & Co. | → $55 | Reiterates | Buy → Buy |
| 06/07/2023 | 218.26% | Wedbush | → $38 | Reiterates | Outperform → Outperform |
| 06/07/2023 | 318.76% | Stifel | $45 → $50 | Maintains | Buy |
| 06/02/2023 | 276.88% | Stifel | $45 → $45 | Maintains | Buy |
| 05/29/2023 | 276.88% | Stifel | $45 → $45 | Maintains | Buy |
| 05/26/2023 | 318.76% | Oppenheimer | → $50 | Reiterates | Outperform → Outperform |
| 05/26/2023 | 218.26% | Wedbush | $31 → $38 | Maintains | Outperform |
| 05/26/2023 | 360.64% | HC Wainwright & Co. | → $55 | Reiterates | Buy → Buy |
| 05/23/2023 | 276.88% | Stifel | $45 → $45 | Maintains | Buy |
| 05/19/2023 | 486.26% | Jefferies | $120 → $70 | Maintains | Buy |
| 05/15/2023 | 276.88% | Stifel | $45 → $45 | Maintains | Buy |
| 05/11/2023 | 276.88% | Stifel | $46 → $45 | Maintains | Buy |
| 05/11/2023 | 360.64% | HC Wainwright & Co. | → $55 | Reiterates | Buy → Buy |
| 05/11/2023 | 318.76% | Oppenheimer | → $50 | Reiterates | Outperform → Outperform |
| 03/15/2023 | 285.26% | Stifel | $55 → $46 | Maintains | Buy |
| 03/02/2023 | 360.64% | HC Wainwright & Co. | → $55 | Reiterates | → Buy |
| 03/01/2023 | 360.64% | Stifel | $58 → $55 | Maintains | Buy |
| 11/14/2022 | 168.01% | Wedbush | $51 → $32 | Maintains | Outperform |
| 11/11/2022 | 360.64% | Morgan Stanley | $60 → $55 | Maintains | Overweight |
| 11/11/2022 | 134.51% | Guggenheim | $55 → $28 | Maintains | Buy |
| 11/10/2022 | 318.76% | Oppenheimer | $80 → $50 | Maintains | Outperform |
| 11/10/2022 | 126.13% | SVB Leerink | $42 → $27 | Maintains | Outperform |
| 11/09/2022 | 385.76% | Stifel | $70 → $58 | Maintains | Buy |
| 08/11/2022 | 402.51% | Morgan Stanley | $95 → $60 | Maintains | Overweight |
| 08/10/2022 | 251.76% | SVB Leerink | $67 → $42 | Maintains | Outperform |
| 08/10/2022 | 360.64% | HC Wainwright & Co. | $120 → $55 | Maintains | Buy |
| 07/29/2022 | 486.26% | Stifel | $72 → $70 | Maintains | Buy |
| 07/12/2022 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 05/05/2022 | 503.02% | Stifel | $74 → $72 | Maintains | Buy |
| 04/12/2022 | 611.89% | Oppenheimer | $100 → $85 | Maintains | Outperform |
| 04/12/2022 | 461.14% | SVB Leerink | $78 → $67 | Maintains | Outperform |
| 04/11/2022 | 519.77% | Stifel | $94 → $74 | Maintains | Buy |
| 04/06/2022 | 461.14% | Wells Fargo | → $67 | Initiates Coverage On | → Overweight |
| 01/20/2022 | 687.27% | Stifel | $88 → $94 | Maintains | Buy |
| 12/17/2021 | 712.4% | SVB Leerink | $89 → $97 | Maintains | Outperform |
| 12/10/2021 | 645.39% | SVB Leerink | $84 → $89 | Maintains | Outperform |
| 11/11/2021 | 905.03% | HC Wainwright & Co. | $80 → $120 | Maintains | Buy |
| 10/27/2021 | 645.39% | Wedbush | $65 → $89 | Maintains | Outperform |
| 09/30/2021 | 603.52% | Stifel | → $84 | Initiates Coverage On | → Buy |
| 09/29/2021 | 653.77% | Oppenheimer | → $90 | Initiates Coverage On | → Outperform |
| 05/21/2021 | 662.14% | UBS | → $91 | Initiates Coverage On | → Buy |
| 05/19/2021 | 570.02% | HC Wainwright & Co. | $65 → $80 | Maintains | Buy |
| 04/13/2021 | 436.01% | SVB Leerink | $60 → $64 | Maintains | Outperform |
| 03/26/2021 | 444.39% | HC Wainwright & Co. | $43 → $65 | Maintains | Buy |
| 01/20/2021 | 444.39% | Wedbush | → $65 | Initiates Coverage On | → Outperform |
| 12/16/2020 | 528.14% | Morgan Stanley | $50 → $75 | Maintains | Overweight |
| 11/11/2020 | 318.76% | Morgan Stanley | $49 → $50 | Maintains | Overweight |
| 09/29/2020 | 268.51% | Cantor Fitzgerald | → $44 | Initiates Coverage On | → Overweight |
| 08/27/2020 | 260.13% | HC Wainwright & Co. | → $43 | Initiates Coverage On | → Buy |
| 08/24/2020 | 310.39% | Morgan Stanley | $45 → $49 | Maintains | Overweight |
| 04/28/2020 | 276.88% | Guggenheim | → $45 | Initiates Coverage On | → Buy |
| 04/28/2020 | 276.88% | SVB Leerink | → $45 | Initiates Coverage On | → Outperform |
| 04/28/2020 | — | Morgan Stanley | Initiates Coverage On | → Overweight | |
| 04/28/2020 | 243.38% | Jefferies | → $41 | Initiates Coverage On | → Buy |
What is the target price for Zentalis Pharma (ZNTL)?
The latest price target for Zentalis Pharma (NASDAQ: ZNTL) was reported by HC Wainwright & Co. on November 7, 2023. The analyst firm set a price target for $46.00 expecting ZNTL to rise to within 12 months (a possible 285.26% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Zentalis Pharma (ZNTL)?
The latest analyst rating for Zentalis Pharma (NASDAQ: ZNTL) was provided by HC Wainwright & Co., and Zentalis Pharma maintained their buy rating.
When is the next analyst rating going to be posted or updated for Zentalis Pharma (ZNTL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zentalis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zentalis Pharma was filed on November 7, 2023 so you should expect the next rating to be made available sometime around November 7, 2024.
Is the Analyst Rating Zentalis Pharma (ZNTL) correct?
While ratings are subjective and will change, the latest Zentalis Pharma (ZNTL) rating was a maintained with a price target of $55.00 to $46.00. The current price Zentalis Pharma (ZNTL) is trading at is $11.94, which is out of the analyst's predicted range.